Barrett's esophagus screening: Difference between revisions
Amresh Kumar (talk | contribs) No edit summary |
Amresh Kumar (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Barret's esophagus is a major risk factor for development of esophageal adenocarcinoma. After diagnosis, regular surveillance is needed based on the grade of dyaplasia. | [[Barret's esophagus]] is a [[major]] [[risk factor]] for [[development]] of [[esophageal adenocarcinoma]]. [[After]] [[diagnosis]], [[regular]] [[surveillance]] is [[needed]] [[based]] on the [[grade]] of [[dyaplasia]]. | ||
* Weak recommendation, moderate-quality evidence: screening in patients with multiple risk factors for esophageal adenocarcinoma: | * [[Weak]] [[recommendation]], [[moderate]]-[[quality]] [[evidence]]: [[screening]] in [[patients]] with [[multiple]] [[risk factors]] for [[esophageal adenocarcinoma]]: | ||
# Age: > 50 years old | # [[Age]] : > 50 years old | ||
# Sex: male | # [[Sex]] : [[male]] | ||
# Race: white | # [[Race]]: [[white]] | ||
# Other: chronic GERD, hiatal hernia, elevated BMI (body mass index),and intraabdominal distribution of body fat. | # Other: chronic [[GERD]], [[hiatal hernia]], [[elevated]] [[BMI]] (body mass index),and [[intraabdominal]] [[distribution]] of [[body]] [[fat]]. | ||
* Strong recommendation, low-quality evidence: | * [[Strong]] [[recommendation]], low-quality [[evidence]]: | ||
# Recommend against screening general population with GERD and no risk factors.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |}}</ref> | # [[Recommend]] [[against]] [[screening]] [[general]] [[population]] [[with]] [[GERD]] and no [[risk factors]].<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |}}</ref> | ||
Revision as of 12:45, 3 November 2017
|
Barrett's Esophagus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Barrett's esophagus screening On the Web |
|
American Roentgen Ray Society Images of Barrett's esophagus screening |
|
Risk calculators and risk factors for Barrett's esophagus screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amresh Kumar MD [2]
Overview
Barret's esophagus is a major risk factor for development of esophageal adenocarcinoma. After diagnosis, regular surveillance is needed based on the grade of dyaplasia.
- Weak recommendation, moderate-quality evidence: screening in patients with multiple risk factors for esophageal adenocarcinoma:
- Age : > 50 years old
- Sex : male
- Race: white
- Other: chronic GERD, hiatal hernia, elevated BMI (body mass index),and intraabdominal distribution of body fat.
- Strong recommendation, low-quality evidence:
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
Weak recommendation, moderate-quality evidence: Endoscopic surveillance in patients with Barrett's esophagus The following intervals are recommended:
- No dysplasia: 3–5 years.
- Low-grade dysplasia: 6–12 months.
- High-grade dysplasia in the absence of eradication therapy: 3 months.[1]
Screening
- There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
- According to the [guideline name], screening for [disease name] is not recommended.
OR
- According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- [Condition 1]
- [Condition 2]
- [Condition 3]